Is MEDP Stock Still the Best Pick Among Its Peers?
Here is how Medpace (MEDP) stacks up against its peers in size, valuation, growth and margin.
- MEDP’s operating margin of 21.2% is high, and higher than most peers – though lower than MTD (28.7%).
- MEDP’s revenue growth of 9.9% in the last 12 months is moderate, outpacing A, PBIO, MTD but lagging ATEC, CERS.
- MEDP’s stock gained 17.0% over the past year with a PE of 31.4, though peers like ATEC delivered stronger returns.
| MEDP | A | ATEC | PBIO | CERS | MTD | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 13.1 | 32.3 | 2.3 | 0.0 | 0.2 | 25.5 |
| Revenue ($ Bil) | 2.2 | 6.6 | 0.7 | 0.0 | 0.2 | 3.8 |
| PE Ratio | 31.4 | 27.7 | -13.7 | -0.0 | -13.1 | 30.0 |
| LTM Revenue Growth | 9.9% | 0.6% | 26.3% | -25.3% | 13.3% | 1.2% |
| LTM Operating Margin | 21.2% | 21.4% | -13.9% | -547.8% | -6.1% | 28.7% |
| LTM FCF Margin | 25.1% | 17.9% | -4.6% | -296.3% | 1.8% | 22.7% |
| 12M Market Return | 17.0% | -14.8% | 149.2% | -99.4% | -38.3% | -10.0% |
Medpace provides global clinical research and development services for drugs and medical devices across all clinical trial phases and multiple therapeutic areas.
Why does this matter? MEDP just went up 34.1% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell MEDP Stock to see if Medpace holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through MEDP Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| MEDP | 9.9% | 11.8% | 29.2% | 27.8% | |
| A | 0.6% | -4.7% | -0.2% | 8.4% | |
| ATEC | 26.3% | 26.8% | 37.4% | 44.3% | |
| PBIO | -25.3% | – | 14.4% | -13.6% | 64.0% |
| CERS | 13.3% | 15.3% | -3.5% | 23.8% | |
| MTD | 1.2% | 2.2% | -3.4% | 5.4% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| MEDP | 21.2% | 21.2% | 17.9% | 19.1% | |
| A | 21.4% | 22.9% | 19.8% | 23.6% | |
| ATEC | -13.9% | -20.1% | -30.7% | -34.5% | |
| PBIO | -547.8% | – | -480.5% | -283.2% | -209.0% |
| CERS | -6.1% | -7.9% | -16.8% | -21.0% | |
| MTD | 28.7% | 29.1% | 28.5% | 28.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| MEDP | 22.9 | 25.4 | 33.3 | 28.0 | |
| A | 28.6 | 30.2 | 33.0 | 35.7 | |
| ATEC | -10.0 | -8.1 | -9.8 | -8.4 | |
| PBIO | -0.0 | – | -0.0 | -0.2 | -0.4 |
| CERS | -14.3 | -13.6 | -10.4 | -15.1 | |
| MTD | 28.9 | 30.1 | 33.6 | 37.3 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.